In March 2016 NICE commenced the review of this guidance, to register as a stakeholder please contact us at email@example.com.
NICE has developed medical technology guidance on the BRAHMS copeptin assay.
NICE medical technology guidance addresses specific technologies notified to NICE by manufacturers. The 'case for adoption' recommendations are based on the claimed advantages of introducing the specific technology compared with current management of the condition. This 'case' is reviewed against the evidence submitted and expert advice. The medical technology guidance on the BRAHMS copeptin assay recommends further research. This recommendation is not intended to preclude the use of the technology in the NHS but to identify further evidence which, after evaluation, could support a recommendation for wider adoption.
NICE has said that at the moment the BRAHMS copeptin assay is promising, but that there is not enough evidence on how it would affect NHS services for it to be used routinely. NICE has recommended that more research on the BRAHMS copeptin assay is done.